Aytu BioPharma Inc (AYTU)
3.17
+0.06
(+1.93%)
USD |
NASDAQ |
May 31, 16:00
3.15
-0.02
(-0.63%)
After-Hours: 20:00
Aytu BioPharma Enterprise Value: 14.59M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 14.59M |
| May 30, 2024 | 14.26M |
| May 29, 2024 | 13.82M |
| May 28, 2024 | 14.70M |
| May 24, 2024 | 14.76M |
| May 23, 2024 | 14.65M |
| May 22, 2024 | 14.32M |
| May 21, 2024 | 14.37M |
| May 20, 2024 | 14.09M |
| May 17, 2024 | 13.31M |
| May 16, 2024 | 13.42M |
| May 15, 2024 | 13.98M |
| May 14, 2024 | 15.43M |
| May 13, 2024 | 15.59M |
| May 10, 2024 | 15.15M |
| May 09, 2024 | 14.81M |
| May 08, 2024 | 14.20M |
| May 07, 2024 | 13.98M |
| May 06, 2024 | 13.98M |
| May 03, 2024 | 13.70M |
| May 02, 2024 | 13.70M |
| May 01, 2024 | 13.05M |
| April 30, 2024 | 12.59M |
| April 29, 2024 | 12.59M |
| April 26, 2024 | 13.11M |
| Date | Value |
|---|---|
| April 25, 2024 | 12.75M |
| April 24, 2024 | 12.53M |
| April 23, 2024 | 12.06M |
| April 22, 2024 | 12.58M |
| April 19, 2024 | 12.47M |
| April 18, 2024 | 12.47M |
| April 17, 2024 | 12.94M |
| April 16, 2024 | 12.86M |
| April 15, 2024 | 11.86M |
| April 12, 2024 | 13.03M |
| April 11, 2024 | 14.31M |
| April 10, 2024 | 14.85M |
| April 09, 2024 | 15.65M |
| April 08, 2024 | 15.31M |
| April 05, 2024 | 14.87M |
| April 04, 2024 | 14.76M |
| April 03, 2024 | 14.37M |
| April 02, 2024 | 13.81M |
| April 01, 2024 | 13.59M |
| March 31, 2024 | 13.87M |
| March 28, 2024 | 13.44M |
| March 27, 2024 | 13.66M |
| March 26, 2024 | 13.66M |
| March 25, 2024 | 13.52M |
| March 22, 2024 | 13.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.837M
Minimum
Sep 14 2023
176.01M
Maximum
Mar 24 2020
42.16M
Average
15.67M
Median
Enterprise Value Benchmarks
| Precision Optics Corp Inc | 40.80M |
| Regen BioPharma Inc | 4.730M |
| Kiora Pharmaceuticals Inc | -18.33M |
| Bioxytran Inc | 20.74M |
| Shuttle Pharmaceuticals Holdings Inc | 5.823M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.887M |
| Revenue (Quarterly) | 17.99M |
| Total Expenses (Quarterly) | 20.21M |
| EPS Diluted (Quarterly) | -0.52 |
| Gross Profit Margin (Quarterly) | 64.99% |
| Profit Margin (Quarterly) | -16.05% |
| Earnings Yield | -82.97% |
| Operating Earnings Yield | 8.88% |
| Normalized Earnings Yield | -17.84 |